Abstract:A sudden increase in the incidence of post‐transplant lymphoproliferative disorder (PTLD) in our cardiac transplant program prompted a retrospective study of 154 consecutive patients to identify predictive variables. The increase was found to be temporally and statistically related to the introduction of the immunosuppressive antibody OKT3. While effective in the treatment of refractory rejection, the value of OKT3 used prophylactically at the time of transplantation remains to be clearly established. Among 75 patients who had not received the drug, PTLD developed in 1 (1.3%) compared with 9 of 79 patients who had (11.4%), a ninefold higher incidence (p = 0.01). The following factors were assessed in a multivariate model: sex; race; age; weight; reason for transplant; rejection episodes; mean cyclosporine level; use and cumulative dose of OKT3, ATG, and steroids. Only the use of OKT3 was significantly associated with development of PTLD (p = 0.001). Increasing risk with increasing dose was evident, in that 4 of 65 patients (6.2%) who received one course of OKT3 (≤ 75 mg) developed PTLD, while 5 of 14 patients (35.7%) who received more than 1 course did so (p 75 mg OKT3, all but one presented with widespread, rapidly progressive disease resulting in early organ failure and death. Among the 14 patients who had received > 75 mg, the interval between courses for those who developed PTLD was much shorter (med 13 days, range 0‐33) than for those who did not (med 115 days, range 8‐884, p = 0.02). There was a strong inverse correlation between total OKT3 dose and the time to appearance of PTLD following transplantation; a mean of 11 ± 4.9 mos. for patients who had received one course, compared to a mean of 1.3 ± 0.45 mos. for those who had received two (p < 0.001). It can be concluded that the addition of OKT3 to a triple drug immunosuppressive regimen increases the incidence of PTLD after cardiac transplantation, and that both the risk and clinical pattern of disease are dose related. No conclusions regarding the mechanism for this increase can be drawn from these data. It is suggested that the risks and benefits of prophylactic OKT3 administration be reassessed, that short intervals between courses be avoided, and that patients who have received the drug be monitored closely for indications of PTLD.

Late reactions during initial OKT‐3 treatment

Immunologic monitoring during OKT3 therapy

Standard versus low‐dose OKT3 induction therapy of cadaveric renal transplants: Comparison of outcome data versus OKT3 dose and serum levels

OKT3 for induction of immunosuppression and treatment of rejection in cardiac allograft recipients

Clinical Study of Single-Dose of Recombinant Humanized Anti-Cd3 Monoclonal Antibody Injection in Kidney Transplant Recipients

Clinical experience with OKT3 monoclonal antibody for treatment of acute renal allograft rejection based on sequential histological evaluation

OKT 3 for rejection reversal in pediatric renal transplantation

OKT3 for induction of immunosuppression in renal transplantation

The use of OKT3 in recipients of pancreatic, pulmonary, and bone marrow allografts

OKT3 for treatment of rejection in renal transplantation

Increased risk of lymphoproliferative disorders following the use of OKT3 in cardiac transplantation

OKT3: Immunology, production, purification, and pharmacokinetics

Aseptic encephalitis and blindness complicating OKT3 therapy

OKT3 and viral disease in pediatric liver transplant recipients

The effect of rabbit antithymocyte serum (RATS) and OKT3 on peripheral blood mononuclear cell subsets following renal transplantation

OKT3 therapy increases cyclosporine blood levels

Human in vivo antigenic modulation of T lymphocytes induced by OKT3 for preventi on of transplant rejection

Treatment of severe rejection of kidney transplants with Orthoclone OKT3

T10B9 (MEDI‐500) mediated immunosuppression: studies on the mechanism of action

Murine monoclonal CD‐3 antibody in cardiac transplantation: Antirejection treatment and preliminary results in a prospectively randomized trial for prophylaxis

Effect of Different Induction Therapies on the Clinical Outcomes of ABO-incompatible Living Donor Kidney Transplantation Recipients